Dengue Vaccine Now Available in the United States
Vaccine Approved for Use in Areas with Risk of Dengue
The dengue vaccine is now available for use in areas with risk of dengue in the United States. The vaccine, Dengvaxia, is approved for use in children and adults aged 9 to 45 years who are living in or traveling to areas with risk of dengue.
Vaccine Prevents Dengue Caused by All Four Serotypes
Dengue is a mosquito-borne virus that can cause a range of symptoms, from mild fever to severe dengue hemorrhagic fever or dengue shock syndrome. The dengue vaccine prevents dengue caused by all four dengue virus serotypes.
Vaccination Does Not Fully Protect Against Dengue
Vaccination with Dengvaxia does not fully protect against dengue, but it can reduce the risk of severe dengue by up to 90%. The vaccine is most effective in people who have never been infected with dengue virus before.
Vaccine Can Be Administered with Other Vaccines
The dengue vaccine can be administered with other vaccines, such as the measles, mumps, and rubella (MMR) vaccine. However, it is important to note that the dengue vaccine should not be administered with the yellow fever vaccine.
Comments